

South East Regional Medicines Optimisation Group (SERMOG) policy recommendation

Title:	Overarching policy on licensed doses or dosing schedules of high-cost drugs not considered in NICE Technology Appraisal (TA) guidance
Number:	SERMOG-02
Category:	Overarching commissioning policy recommendation
Date determined by SERMOG:	September 2024

Policy recommendation:	
<p>The South East Regional Medicines Optimisation Group (SERMOG) considered national guidance, the baseline position, other integrated care board (ICB) policies, equality and equity issues and the potential impact of a new policy.</p> <p>All decisions were made with reference to the South East Region Policy Recommendation Committees' Ethical Framework. Taking these into account, the SERMOG recommends:</p> <ul style="list-style-type: none"> • Doses or dosing schedules of high-cost drugs not appraised in NICE TA guidance are non-formulary and need to be considered through the agreed local processes for population-based commissioning*, before they can be made available for use**. • This position does not apply to the dosing schedules of high-cost drugs included in locally or nationally agreed treatment pathways or clinical guidance. It should be viewed as general overarching guidance. <p><i>* Once it has been established with NICE that there are no plans to update the relevant NICE TA guidance to include licensed doses/ dosing schedules not previously considered.</i></p> <p><i>** Patients already receiving the intervention may continue until they and their NHS clinician consider it appropriate to stop. Note, this statement does not apply to patients receiving treatment as part of a clinical trial.</i></p>	
Version control:	
Final Version 1.0 – Circulated to ICBs for ratification on 9 October 2024	
Notes:	
<p>This policy recommendation will be reviewed when new information becomes available that is likely to have a material effect on the current recommendation.</p> <p>South East region ICBs will always consider appropriate individual funding requests (IFRs) through their IFR processes.</p>	